Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Clayton S. Spada is active.

Publication


Featured researches published by Clayton S. Spada.


European Journal of Pharmacology | 1993

Further studies on ocular responses to DP receptor stimulation

David F. Woodward; Clayton S. Spada; Stephen B. Hawley; Linda S. Williams; Charles E. Protzman; Amelia L. Nieves

Prostaglandin D2 (PGD2) and the selective DP receptor agonist BW 245C have been previously shown to lower intraocular pressure in rabbits, while PGD2, but not BW 245C, caused plasma extravasation, eosinophil infiltration, and goblet cell depletion. In these present studies definition of the ocular pharmacology of prostaglandin D2 (PGD2) has been extended by using a further selective DP receptor agonist SQ 27986 and a potent and selective DP receptor antagonist BW A868C. In cats and rabbits SQ 27986 caused ocular hypotension. The ocular hypotensive effect of PGD2 in rabbits was blocked by pretreatment with the DP receptor antagonist BW A868C, whereas the activities of PGE2 and PGF2 alpha remained unaltered. The singular involvement of the DP receptor in changes in rabbit intraocular pressure evoked by PGD2 was thereby verified by using the antagonist BW A868C. In terms of effects on the ocular surface, SQ 27986 caused no increase in conjunctival microvascular permeability, no eosinophil infiltration, and no depletion of the goblet cell population. These findings reinforce the concept that selective DP receptor agonists may be useful for lowering intraocular pressure without causing ocular surface pathology. PGD2 induced increases in conjunctival microvascular permeability were inhibited by BW A868C, despite the fact that DP receptor agonists failed to evoke a plasma exudation response. This finding was unexpected and suggests a possible subdivision of the DP receptor designation.


Prostaglandins | 1986

Leukotrienes cause eosinophil emigration into conjunction tissue

Clayton S. Spada; Daivd F. Woodward; Stephen B. Hawley; Amelia L. Nieves

The ability of LTB4, LTC4, the 5S,6R and 5R,6S LTD4 stereoisomers, and LTE4 to evoke leukocyte infiltration into the conjunctiva was demonstrated in the guinea pig by histological and light microscopy techniques. LTD4 and LTE4 demonstrated a dose-dependent and predominantly eosinophilic infiltrate over the selected dose range (10 ng to 1000 ng), while there was only a minimal response to LTC4. LTB4 produced marked eosinophil infiltrates only at the highest dose; scattered neutrophil infiltrates were also noted at the high dose of LTB4. The 5R,6S LTD4 stereoisomer did not evoke any leukocyte infiltration. The SRS-A antagonist, FPL 55712, abolished peptidoleukotriene-induced eosinophil emigration, and indomethacin pre-treatment had no inhibitory effect, indicating direct mediation of this response by LTs. Histamine caused a comparable eosinophilia over a dose range of 10 micrograms to 1000 micrograms. LT-induced eosinophil emigration was directed to the conjunctival epithelium; the cells appeared intact and no tissue damage was observed. These results may have relevance in the areas of allergic conjunctivitis and asthma research.


European Journal of Pharmacology | 1989

Platelet-activating factor causes goblet cell depletion in the conjunctiva

David F. Woodward; Clayton S. Spada; Amelia L. Nieves; Stephen B. Hawley; Linda S. Williams

Platelet-activating factor (PAF) (1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) produced dose-dependent depletion of the goblet cell population associated with the conjunctival epithelium. Reductions in goblet cell numbers did not correspond to leukocyte infiltration and were consistent with a direct effect of PAF. In contrast, LTD4 and LTE4 did not affect the goblet cell population although they caused massive eosinophil infiltration into the conjunctival epithelium. Histamine also produced conjunctival goblet cell depletion, but this appeared secondary to eosinophil degranulation and resultant epithelial desquamation. In addition to goblet cell expulsion, PAF produced an increase in conjunctival microvascular permeability over an identical dose-range. PAF-induced leukocyte emigration was small or absent and comprised a neutrophil infiltrate which exhibited no clear dose-dependent relationship. Lyso-PAF produced effects only at the highest dose employed where pathological changes and a distinct increase in conjunctival microvascular permeability were evident. Lyso-PAF- and PAF-induced increases in conjunctival microvascular permeability were virtually abolished by the PAF antagonist CV-6209. The pronounced inhibitory activity of CV-6209 suggests that high doses of lyso-PAF may either weakly stimulate conjunctival PAF receptors or that there may be sufficient conversion of lyso-PAF to biologically active levels of PAF.


Journal of Ocular Pharmacology and Therapeutics | 2001

Differential Effects of α-Adrenoceptor Agonists on Human Retinal Microvessel Diameter

Clayton S. Spada; Amelia L. Nieves; James A. Burke; Larry A. Wheeler; David F. Woodward

The effects of locally administered brimonidine, clonidine, and p-aminoclonidine on microvessel caliber were compared in human retinal tissues grafted into the hamster cheek pouch. Clonidine and p-aminoclonidine, but not brimonidine, potently constricted human retinal microvessels over a broad concentration range. All three agonists elicited significant vasoconstriction in naive hamster cheek pouch microvasculature. The α2-adrenoceptor antagonist, rauwolscine, inhibited p-aminoclonidine-induced constriction in naive hamster cheek pouch microvessels, but not p-aminoclonidine-induced effects in retinal grafts. Selective α1-adrenoceptor agonists evoked vasoconstriction in retinal grafts only at relatively high concentrations. These differential effects on the retinal microvasculature could not be readily explained solely on the basis of α1- or α2-adrenoceptor involvement. Clonidine, p-aminoclonidine and brimonidine are also imidazoline derivatives that interact with putative non-adrenergic imidazoline-sensit...


Journal of Ocular Pharmacology and Therapeutics | 1995

The Pruritogenic and Inflammatory Effects of Prostanoids in the Conjunctiva

David F. Woodward; Amelia L. Nieves; Stephen B. Hawley; Romesh Joseph; Garrett F. Merlino; Clayton S. Spada


Experimental Eye Research | 2005

Bimatoprost and prostaglandin F2α selectively stimulate intracellular calcium signaling in different cat iris sphincter cells

Clayton S. Spada; Achim H.-P. Krauss; David F. Woodward; J. Chen; Charles E. Protzman; Amelia L. Nieves; Larry A. Wheeler; David Scott; George Sachs


Archive | 2002

Glaucoma treatments with reduced hyperpigmentation

David F. Woodward; Licheng Shi; Achim H.-P. Krauss; Clayton S. Spada; Sheila Mac Neil; Linda C. Smith-Thomas


Experimental Eye Research | 2004

Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent.

Linda C. Smith-Thomas; Manar Moustafa; Clayton S. Spada; L Shi; Rebecca A. Dawson; M. Wagner; Chariklia Balafa; K.M Kedzie; J.W Reagan; Achim H.-P. Krauss; David F. Woodward; Sheila MacNeil


Archive | 2001

Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation

David F. Woodward; Licheng Shi; Achim H.-P. Krauss; Clayton S. Spada; Sheila Mac Neil; Linda C. Smith-Thomas


Experimental Eye Research | 2002

Vascular activities of prostaglandins and selective prostanoid receptor agonists in human retinal microvessels

Clayton S. Spada; Amelia L. Nieves; David F. Woodward

Collaboration


Dive into the Clayton S. Spada's collaboration.

Top Co-Authors

Avatar

Achim H.-P. Krauss

Howard Hughes Medical Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sheila Mac Neil

Northern General Hospital

View shared research outputs
Top Co-Authors

Avatar

David Scott

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

George Sachs

United States Department of Veterans Affairs

View shared research outputs
Researchain Logo
Decentralizing Knowledge